Correction: Pharma E
Correction: Pharma Equity Group A/S - Årsrapport 2023
March 20, 2024 12:15 ET | Pharma Equity Group A/S
Correction: Adding Annual Report in xhtml-file zip-format  Pharma Equity Group A/S - Årsrapport 2023 Dato: 20. marts 2024 Årets meddelelse nr.: 07 Pharma Equity Group A/S - Årsrapport...
Correction: Pharma E
Correction: Pharma Equity Group A/S - Annual Report 2023
March 20, 2024 12:15 ET | Pharma Equity Group A/S
Correction: Adding Annual Report in xhtml-file zip-format  Pharma Equity Group A/S - Annual Report 2023 Date: March 20, 2024Announcement of the Year No.: 7 Pharma Equity Group A/S - Annual...
Pharma Equity Group
Pharma Equity Group A/S - Årsrapport 2023
March 20, 2024 03:58 ET | Pharma Equity Group A/S
Pharma Equity Group A/S - Årsrapport 2023 Dato: 20. marts 2024 Årets meddelelse nr.: 07 Pharma Equity Group A/S - Årsrapport 2023 - året i hovedtræk Bestyrelsen for Pharma Equity Group A/S har dags...
Pharma Equity Group
Pharma Equity Group A/S - Annual Report 2023
March 20, 2024 03:58 ET | Pharma Equity Group A/S
Pharma Equity Group A/S - Annual Report 2023 Date: March 20, 2024Announcement of the Year No.: 7 Pharma Equity Group A/S - Annual report 2023 - main features of the year Today, the Board of...
Pharma Equity Groups
Pharma Equity Groups datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse fra Det Europæiske Patentkontor (EPO) om beslutningen om at tildele deres patent for lægemiddelsammensætninger til fremme af sårheling (RNX-022).
March 05, 2024 04:11 ET | Pharma Equity Group A/S
Pharma Equity Groups datterselskab (Reponex Pharmaceuticals A/S) har modtaget meddelelse fra Det Europæiske Patentkontor (EPO) om beslutningen om at tildele deres patent for lægemiddelsammensætninger...
Pharma Equity Group'
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for promoting the healing of wounds (RNX-022).
March 05, 2024 04:11 ET | Pharma Equity Group A/S
Pharma Equity Group's subsidiary (Reponex Pharmaceuticals A/S) has received notification from the European Patent Office (EPO) regarding the decision to grant their patent for drug compositions for...
Tegning af konvertib
Tegning af konvertible lån fuldført
February 07, 2024 07:38 ET | Pharma Equity Group A/S
7. februar 2024 Selskabsmeddelelse nr. 05 Tegning af konvertible lån fuldført Bestyrelsen i Pharma Equity Group besluttede den 7. februar 2024 at udstede konvertible lån i overensstemmelse...
Completion of subscr
Completion of subscription of convertible loans
February 07, 2024 07:38 ET | Pharma Equity Group A/S
7 February 2024 Company Announcement No. 05 Completion of subscription of convertible loans On 7 February 2024 the Board of Directors in Pharma Equity Group decided to issue convertible...
Bestyrelsens beslutn
Bestyrelsens beslutning om udstedelse af konvertible lån
February 07, 2024 03:46 ET | Pharma Equity Group A/S
     Bestyrelsens beslutning om udstedelse af konvertible lån  7. februar 2024Meddelelse nr. 04 Bestyrelsen i Pharma Equity Group har truffet beslutning om udstedelse af yderligere konvertible lån i...
The Board of Directo
The Board of Director's decision to issue convertible loans
February 07, 2024 03:46 ET | Pharma Equity Group A/S
     The Board of Director's decision to issue convertible loans  7 February 2024Company Announcement no. 04 The Board of Directors of Pharma Equity Group has decided on the issuance of additional...